| Drug Name |
Lorcaserin hydrochloride |
| Drug ID |
BADD_D01319 |
| Description |
Lorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety. Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride. |
| Indications and Usage |
For the treatment of obesity, as an adjunct to a reduced-calorie diet and increased physical activity. |
| Marketing Status |
approved |
| ATC Code |
A08AA11 |
| DrugBank ID |
DB04871
|
| KEGG ID |
D06613
|
| MeSH ID |
C506658
|
| PubChem ID |
11673085
|
| TTD Drug ID |
D01JMC
|
| NDC Product Code |
14501-0023 |
| UNII |
0QJF08GDPE
|
| Synonyms |
lorcaserin | (1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine | Belviq | AR-10A | 8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine | APD 356 | APD356 | APD-356 |
